Hyperbaric oxygen in cancer patients: a review of clinical safety, tissue selectivity, and therapeutic synergy

Background For decades, the clinical application of Hyperbaric Oxygen Therapy (HBOT) in oncology has been constrained by theoretical concerns that hyperoxia might act as an unintended proliferative accelerator or tumor “fertilizer” by encouraging angiogenesis. This comprehensive review synthesizes the historical context, systematic review data, mechanistic literature, and clinical evidence to resolve three distinct questions: whether HBOT is safe in cancer patients, why its physiological effects diverge between healthy and malignant tissues, and how it can be leveraged synergistically with standard and novel oncological modalities. Safety Findings The human clinical record demonstrates a consistent, reproducible record of clinical safety across published cohorts. More than 38 independent human clinical reports published since 1970 have examined HBOT in cancer patients, and all found no association with tumor growth, recurrence, or metastasis. This consistency is reinforced by 19 randomized trials comprising 1,103 tumor-bearing patients prospectively evaluated under hyperoxia, none of which showed malignant acceleration at any site. A mathematical power analysis applied to this clinical corpus demonstrates that the probability of a genuine, undetected oncological hazard is less than 1 × 10 − 11. Tissue Selectivity and Mechanisms This safety profile rests on fundamental tissue selectivity. While intermittent hyperoxia drives tissue regeneration and upregulates antioxidant defenses in healthy host cells, malignant cells operating under the Warburg phenotype—characterized by severe mitochondrial structural degradation and cristolysis—possess a compressed redox margin. By reversing microenvironmental tumor hypoxia, hyperbaric oxygen destabilizes HIF-1alpha, suppresses glycolytic enzyme machinery, induces intrinsic mitochondrial apoptosis, and reverses epithelial-to-mesenchymal transition. Therapeutic Synergy Beyond clinical safety, hyperbaric hyperoxia acts as a potent therapeutic sensitizer. In randomized trials, adding HBOT to radiotherapy significantly reduced mortality and local recurrence in head and neck cancers. Mechanistically, HBOT dismantles dense extracellular matrix barriers, rebalances immunosuppressive myeloid components, and enhances T-cell infiltration, providing a clear rationale for combination with immunotherapies, chemotherapies, and ketogenic metabolic therapy. Conclusion Active or historical malignancy is not a valid contraindication for hyperbaric oxygen intervention. Hyperbaric oxygen functions as a tissue-selective biological signal—safe in healthy host tissue, disruptive to malignant survival architecture, and synergistic with modern oncological therapeutics.